glp 1 agonist and alcohol use disorder GLP-1s Hold Promise as Treatment for GLP-1 Receptor Agonists as Treatments

Preclinical studies suggest that dual GLP-1/GIP agonism enhances endothelial function, reduces vascular inflammation, and promotes plaque stability more effectively than GLP-1 alone, potentially via amplified cAMP signalling and GIP-mediated anti-lipolytic effects [52]

10.3390/ph16081065 3 AthaudaD.FoltynieT

doi: 10.3390/genes10100798 [DOI] [PMC free article] [PubMed] [Google Scholar] 49

T., Laven, J

L., Land, L

A Morgan Stanley AlphaWise survey of senior human resources executives showed that the percentage of employers covering GLP-1s for obesity rose from 44% in 2024 to 48% last year, with respondents projecting it to reach 65% by 2027